Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine plus Venetoclax in higher-risk CMML
2021-002007-35Phase 2Active
- Sponsor
- Groupe Français des Myélodysplasies
- Start
- Dec 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax and azacitidine in chronic myelomonocytic leukemia (CMML), sponsored by Groupe Français des Myélodysplasies. Primary endpoint: Dose-limiting toxicity within first two cycles. Started Dec 2022; status: active.
02
Drugs
venetoclaxazacitidine
03
Conditions
chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on 2021-002007-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002007-35.